Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 29

1.

The growth of AKI: half empty or half full, it's the size of the glass that matters.

Hsu RK, Siew ED.

Kidney Int. 2017 Sep;92(3):550-553. doi: 10.1016/j.kint.2017.04.047.

PMID:
28807263
2.

Recent trends in the prevalence of chronic kidney disease: not the same old song.

Hsu RK, Powe NR.

Curr Opin Nephrol Hypertens. 2017 May;26(3):187-196. doi: 10.1097/MNH.0000000000000315.

PMID:
28319485
3.

The Role of Acute Kidney Injury in Chronic Kidney Disease.

Hsu RK, Hsu CY.

Semin Nephrol. 2016 Jul;36(4):283-92. doi: 10.1016/j.semnephrol.2016.05.005. Review.

4.

Utilizing electronic health records to predict acute kidney injury risk and outcomes: workgroup statements from the 15(th) ADQI Consensus Conference.

Sutherland SM, Chawla LS, Kane-Gill SL, Hsu RK, Kramer AA, Goldstein SL, Kellum JA, Ronco C, Bagshaw SM; 15 ADQI Consensus Group.

Can J Kidney Health Dis. 2016 Feb 26;3:11. doi: 10.1186/s40697-016-0099-4. eCollection 2016. Review.

5.

Abrupt Decline in Kidney Function Before Initiating Hemodialysis and All-Cause Mortality: The Chronic Renal Insufficiency Cohort (CRIC) Study.

Hsu RK, Chai B, Roy JA, Anderson AH, Bansal N, Feldman HI, Go AS, He J, Horwitz EJ, Kusek JW, Lash JP, Ojo A, Sondheimer JH, Townsend RR, Zhan M, Hsu CY; CRIC Study Investigators.

Am J Kidney Dis. 2016 Aug;68(2):193-202. doi: 10.1053/j.ajkd.2015.12.025. Epub 2016 Jan 29.

6.

Exploring Potential Reasons for the Temporal Trend in Dialysis-Requiring AKI in the United States.

Hsu RK, McCulloch CE, Heung M, Saran R, Shahinian VB, Pavkov ME, Burrows NR, Powe NR, Hsu CY; Centers for Disease Control and Prevention Chronic Kidney Disease Surveillance Team.

Clin J Am Soc Nephrol. 2016 Jan 7;11(1):14-20. doi: 10.2215/CJN.04520415. Epub 2015 Dec 18.

7.

Elevated BP after AKI.

Hsu CY, Hsu RK, Yang J, Ordonez JD, Zheng S, Go AS.

J Am Soc Nephrol. 2016 Mar;27(3):914-23. doi: 10.1681/ASN.2014111114. Epub 2015 Jul 1.

8.

Regional variation in the incidence of dialysis-requiring AKI in the United States.

Hsu RK, McCulloch CE, Ku E, Dudley RA, Hsu CY.

Clin J Am Soc Nephrol. 2013 Sep;8(9):1476-81. doi: 10.2215/CJN.12611212. Epub 2013 Aug 8.

9.

Temporal trends in prevalence of CKD: the glass is half full and not half empty.

Hsu RK, Hsu CY.

Am J Kidney Dis. 2013 Aug;62(2):214-6. doi: 10.1053/j.ajkd.2013.05.003. No abstract available.

10.

Temporal changes in incidence of dialysis-requiring AKI.

Hsu RK, McCulloch CE, Dudley RA, Lo LJ, Hsu CY.

J Am Soc Nephrol. 2013 Jan;24(1):37-42. doi: 10.1681/ASN.2012080800. Epub 2012 Dec 6.

11.

We can diagnose AKI "early".

Hsu RK, Hsu CY.

Clin J Am Soc Nephrol. 2012 Nov;7(11):1741-2. doi: 10.2215/CJN.09740912. Epub 2012 Oct 11. No abstract available.

12.

Fine-mapping classical HLA variation associated with durable host control of HIV-1 infection in African Americans.

McLaren PJ, Ripke S, Pelak K, Weintrob AC, Patsopoulos NA, Jia X, Erlich RL, Lennon NJ, Kadie CM, Heckerman D, Gupta N, Haas DW, Deeks SG, Pereyra F, Walker BD, de Bakker PI; International HIV Controllers Study.

Hum Mol Genet. 2012 Oct 1;21(19):4334-47. doi: 10.1093/hmg/dds226. Epub 2012 Jun 19.

13.

Acute kidney injury: comment on "trends in the incidence of acute kidney injury in patients hospitalized with acute myocardial infarction".

Hsu RK, Hsu CY.

Arch Intern Med. 2012 Feb 13;172(3):253-4. doi: 10.1001/archinternmed.2011.1606. No abstract available.

14.

A randomized, double-blind, controlled study of NGX-4010, a capsaicin 8% dermal patch, for the treatment of painful HIV-associated distal sensory polyneuropathy.

Clifford DB, Simpson DM, Brown S, Moyle G, Brew BJ, Conway B, Tobias JK, Vanhove GF; NGX-4010 C119 Study Group.

J Acquir Immune Defic Syndr. 2012 Feb 1;59(2):126-33. doi: 10.1097/QAI.0b013e31823e31f7.

PMID:
22067661
15.

Proteinuria and reduced glomerular filtration rate as risk factors for acute kidney injury.

Hsu RK, Hsu CY.

Curr Opin Nephrol Hypertens. 2011 May;20(3):211-7. doi: 10.1097/MNH.0b013e3283454f8d. Review.

16.

The major genetic determinants of HIV-1 control affect HLA class I peptide presentation.

International HIV Controllers Study, Pereyra F, Jia X, McLaren PJ, Telenti A, de Bakker PI, Walker BD, Ripke S, Brumme CJ, Pulit SL, Carrington M, Kadie CM, Carlson JM, Heckerman D, Graham RR, Plenge RM, Deeks SG, Gianniny L, Crawford G, Sullivan J, Gonzalez E, Davies L, Camargo A, Moore JM, Beattie N, Gupta S, Crenshaw A, Burtt NP, Guiducci C, Gupta N, Gao X, Qi Y, Yuki Y, Piechocka-Trocha A, Cutrell E, Rosenberg R, Moss KL, Lemay P, O'Leary J, Schaefer T, Verma P, Toth I, Block B, Baker B, Rothchild A, Lian J, Proudfoot J, Alvino DM, Vine S, Addo MM, Allen TM, Altfeld M, Henn MR, Le Gall S, Streeck H, Haas DW, Kuritzkes DR, Robbins GK, Shafer RW, Gulick RM, Shikuma CM, Haubrich R, Riddler S, Sax PE, Daar ES, Ribaudo HJ, Agan B, Agarwal S, Ahern RL, Allen BL, Altidor S, Altschuler EL, Ambardar S, Anastos K, Anderson B, Anderson V, Andrady U, Antoniskis D, Bangsberg D, Barbaro D, Barrie W, Bartczak J, Barton S, Basden P, Basgoz N, Bazner S, Bellos NC, Benson AM, Berger J, Bernard NF, Bernard AM, Birch C, Bodner SJ, Bolan RK, Boudreaux ET, Bradley M, Braun JF, Brndjar JE, Brown SJ, Brown K, Brown ST, Burack J, Bush LM, Cafaro V, Campbell O, Campbell J, Carlson RH, Carmichael JK, Casey KK, Cavacuiti C, Celestin G, Chambers ST, Chez N, Chirch LM, Cimoch PJ, Cohen D, Cohn LE, Conway B, Cooper DA, Cornelson B, Cox DT, Cristofano MV, Cuchural G Jr, Czartoski JL, Dahman JM, Daly JS, Davis BT, Davis K, Davod SM, DeJesus E, Dietz CA, Dunham E, Dunn ME, Ellerin TB, Eron JJ, Fangman JJ, Farel CE, Ferlazzo H, Fidler S, Fleenor-Ford A, Frankel R, Freedberg KA, French NK, Fuchs JD, Fuller JD, Gaberman J, Gallant JE, Gandhi RT, Garcia E, Garmon D, Gathe JC Jr, Gaultier CR, Gebre W, Gilman FD, Gilson I, Goepfert PA, Gottlieb MS, Goulston C, Groger RK, Gurley TD, Haber S, Hardwicke R, Hardy WD, Harrigan PR, Hawkins TN, Heath S, Hecht FM, Henry WK, Hladek M, Hoffman RP, Horton JM, Hsu RK, Huhn GD, Hunt P, Hupert MJ, Illeman ML, Jaeger H, Jellinger RM, John M, Johnson JA, Johnson KL, Johnson H, Johnson K, Joly J, Jordan WC, Kauffman CA, Khanlou H, Killian RK, Kim AY, Kim DD, Kinder CA, Kirchner JT, Kogelman L, Kojic EM, Korthuis PT, Kurisu W, Kwon DS, LaMar M, Lampiris H, Lanzafame M, Lederman MM, Lee DM, Lee JM, Lee MJ, Lee ET, Lemoine J, Levy JA, Llibre JM, Liguori MA, Little SJ, Liu AY, Lopez AJ, Loutfy MR, Loy D, Mohammed DY, Man A, Mansour MK, Marconi VC, Markowitz M, Marques R, Martin JN, Martin HL Jr, Mayer KH, McElrath MJ, McGhee TA, McGovern BH, McGowan K, McIntyre D, Mcleod GX, Menezes P, Mesa G, Metroka CE, Meyer-Olson D, Miller AO, Montgomery K, Mounzer KC, Nagami EH, Nagin I, Nahass RG, Nelson MO, Nielsen C, Norene DL, O'Connor DH, Ojikutu BO, Okulicz J, Oladehin OO, Oldfield EC 3rd, Olender SA, Ostrowski M, Owen WF Jr, Pae E, Parsonnet J, Pavlatos AM, Perlmutter AM, Pierce MN, Pincus JM, Pisani L, Price LJ, Proia L, Prokesch RC, Pujet HC, Ramgopal M, Rathod A, Rausch M, Ravishankar J, Rhame FS, Richards CS, Richman DD, Rodes B, Rodriguez M, Rose RC 3rd, Rosenberg ES, Rosenthal D, Ross PE, Rubin DS, Rumbaugh E, Saenz L, Salvaggio MR, Sanchez WC, Sanjana VM, Santiago S, Schmidt W, Schuitemaker H, Sestak PM, Shalit P, Shay W, Shirvani VN, Silebi VI, Sizemore JM Jr, Skolnik PR, Sokol-Anderson M, Sosman JM, Stabile P, Stapleton JT, Starrett S, Stein F, Stellbrink HJ, Sterman FL, Stone VE, Stone DR, Tambussi G, Taplitz RA, Tedaldi EM, Telenti A, Theisen W, Torres R, Tosiello L, Tremblay C, Tribble MA, Trinh PD, Tsao A, Ueda P, Vaccaro A, Valadas E, Vanig TJ, Vecino I, Vega VM, Veikley W, Wade BH, Walworth C, Wanidworanun C, Ward DJ, Warner DA, Weber RD, Webster D, Weis S, Wheeler DA, White DJ, Wilkins E, Winston A, Wlodaver CG, van't Wout A, Wright DP, Yang OO, Yurdin DL, Zabukovic BW, Zachary KC, Zeeman B, Zhao M.

Science. 2010 Dec 10;330(6010):1551-7. doi: 10.1126/science.1195271. Epub 2010 Nov 4.

17.

Quantitative trait loci for CD4:CD8 lymphocyte ratio are associated with risk of type 1 diabetes and HIV-1 immune control.

Ferreira MA, Mangino M, Brumme CJ, Zhao ZZ, Medland SE, Wright MJ, Nyholt DR, Gordon S, Campbell M, McEvoy BP, Henders A, Evans DM, Lanchbury JS, Pereyra F; International HIV Controllers Study, Walker BD, Haas DW, Soranzo N, Spector TD, de Bakker PI, Frazer IH, Montgomery GW, Martin NG.

Am J Hum Genet. 2010 Jan;86(1):88-92. doi: 10.1016/j.ajhg.2009.12.008. Epub 2009 Dec 31.

18.

Modulation of K65R selection by zidovudine inclusion: analysis of HIV resistance selection in subjects with virologic failure receiving once-daily abacavir/lamivudine/zidovudine and tenofovir DF (study COL40263).

Ross L, Elion R, Lanier R, Dejesus E, Cohen C, Redfield RR, Gathe JC, Hsu RK, Yau L, Paulsen D, Ha B; COL40263 Study Team.

AIDS Res Hum Retroviruses. 2009 Jul;25(7):665-72. doi: 10.1089/aid.2008.0302.

PMID:
19563238
19.

Subgroup analyses of maraviroc in previously treated R5 HIV-1 infection.

Fätkenheuer G, Nelson M, Lazzarin A, Konourina I, Hoepelman AI, Lampiris H, Hirschel B, Tebas P, Raffi F, Trottier B, Bellos N, Saag M, Cooper DA, Westby M, Tawadrous M, Sullivan JF, Ridgway C, Dunne MW, Felstead S, Mayer H, van der Ryst E; MOTIVATE 1 and MOTIVATE 2 Study Teams.

N Engl J Med. 2008 Oct 2;359(14):1442-55. doi: 10.1056/NEJMoa0803154.

20.

Maraviroc for previously treated patients with R5 HIV-1 infection.

Gulick RM, Lalezari J, Goodrich J, Clumeck N, DeJesus E, Horban A, Nadler J, Clotet B, Karlsson A, Wohlfeiler M, Montana JB, McHale M, Sullivan J, Ridgway C, Felstead S, Dunne MW, van der Ryst E, Mayer H; MOTIVATE Study Teams.

N Engl J Med. 2008 Oct 2;359(14):1429-41. doi: 10.1056/NEJMoa0803152.

Supplemental Content

Loading ...
Support Center